Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

PHASE3TerminatedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

October 3, 2012

Primary Completion Date

May 21, 2018

Study Completion Date

June 29, 2018

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Idelalisib

Idelalisib tablet(s) administered orally twice daily

Trial Locations (45)

10021

Weill Cornell Medical College, New York

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10126

Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino

11042

Long Island Jewish Medical Center, New Hyde Park

20007

Georgetown University Medical Center Lombardi Cancer Center, Washington D.C.

20132

Ospedale San Raffaele S.r.l., Milan

22031

Virginia Cancer Specialists, PC, Fairfax

24014

Oncology and Hematology Associates of Southwest Virginia, Inc., Roanoke

29605

Cancer Centers of the Carolinas, Greenville

33435

Collaborative Research Group, Boynton Beach

33705

Florida Cancer Specialists, St. Petersburg

33916

Florida Cancer Specialists, Fort Myers

35805

Clearview Cancer Institute, Huntsville

37203

Sarah Cannon Research Institute, Nashville

50937

Universitätsklinikum Köln, Cologne

53226

Medical College of Wisconsin, Milwaukee

60611

Northwestern University, Chicago

69495

Centre Hospitalier Lyon Sud, Pierre-Bénite

76038

Centre Henri Becquerel, Rouen

76104

Texas Oncology, P.A., Fort Worth

77030

M.D. Anderson Cancer Center, Houston

78217

Cancer Care Network of South Texas, San Antonio

80218

Rocky Mountain Blood and Marrow Transplant Program, Denver

Rocky Mountain Cancer Center, Denver

85704

Arizona Oncology Associates, Tucson

90404

UCLA, Santa Monica

91052

Hämatologische und Internistische Gemeinschaftspraxis Dres. Eckart / Häcker, Erlangen

92093

University of California, San Diego - Moores Cancer Center, La Jolla

93030

Ventura County Hematology Oncology Specialists, Oxnard

94305

Stanford Cancer Center, Stanford

97062

Northwest Cancer Specialists, PC, Tualatin

97477

Willamette Valley Cancer Center, Springfield

98902

Yakima Valley Memorial Hospital/North Star Lodge, Yakima

07601

Hackensack University Medical Center, Hackensack

98109-1024

Seattle Cancer Care Alliance, Seattle

BH7 7DW

Royal Bournemouth Hospital, Bournemouth

CB2 0QQ

Addenbrooke's Hospital, Cambridge

DT1 2JY

Dorset County Hospital, Dorchester

HA1 3UJ

Northwick Park Hospital, Harrow

LS9 7TF

St James's University Hospital, Leeds

L7 8XP

Royal Liverpool University Hospital, Liverpool

W12 0NN

Hammersmith Hospital, London

BR6 8ND

Princess Royal University Hospital, Orpington

SO16 6YD

Southampton General Hospital, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01539291 - Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | Biotech Hunter | Biotech Hunter